trending Market Intelligence /marketintelligence/en/news-insights/trending/q9PzGEUX3vj6jXW6X08yjg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Repros Therapeutics likely to get negative EU opinion on hypogonadism drug

Repros Therapeutics Inc. said its marketing application for enclomiphene in secondary hypogonadism is likely to receive a negative opinion in January 2018 from a European Medicines Agency committee.

The company received feedback regarding the forthcoming option, which will be issued by the Committee for Medicinal Products for Human Use, following an oral explanation.

The application was submitted by Renable Pharma Ltd., the company's U.K. unit.

Hypogonadism is a form of testosterone deficiency in adult males.

Allergan plc is in the process of acquiring Repros Therapeutics.